Mallinckrodt plc company logo

# 1st Gen Model Mallinckrodt plc Pharmaceutical preparations

  • $45.37Last close price
    at 22-jun-2017
  • Subscribe >> Deal exit on
    June 23, 2017
    Deal entry on
    June 23, 2017
  • 6.02%Expected margin
  • 67.24% successful of 58 deals

MNK

Model's trade recommendations 11.13% Return for period

9.32% Annual return

$4.51B Market Cap

β 1.52  

MNK

Model (following trade recommendations)

MNK

Underlying stock

S&P 500

Index
Return for period 11.13%
10.66%
1.78%
52wk return -10.74%
-22.74%
16.82%
52wk Range
39.63—83.06
2000.54—2399.63
Sortino ratio 0.62
Sharpe ratio 0.48
Norm. RMSE 0.53%
Downside risk 18.85%
Volatility 24.18%
  • STRONG BUY Analysts consensus recommendation

Mallinckrodt Plc. is engaged in pharmaceuticals business. It develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The company's Specialty Pharmaceuticals segment includes branded and generic drugs and Medical Imaging segment includes contrast media and nuclear imaging agents. Mallinckrodt Plc. is based in Dublin, Ireland.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Mallinckrodt plc (MNK) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 22, 2015.

Market data for MNK model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 99M
P/E 5.79
Shares Outstanding 99M
% Held by Insiders 0.77%
% Held by Institutions 96.96%
EPS (last reported FY) $NaN
EPS (last reported Q) $1.68
EPS, estimated (last reported Q) $1.63
Total revenues $1 B
Net income $-0 B